Nanotherapeutic Delivery of Resveratrol Analogs as a Pre-Treatment of Allografts in Solid Organ Transplantation
Nanotherapeutic Delivery of Resveratrol Analogs as a Pre-Treatment of Allografts in Solid Organ Transplantation
批准号:
9034163
负责人:
ANN-MARIE BROOME
金额:
$7.48万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-07-01 至 2018-04-30
关键词:
AcuteAddressAdverse effectsAllograftingAmino Acid SequenceAnti-Inflammatory AgentsAnti-inflammatoryAntigen PresentationAntioxidantsBindingBiological AvailabilityBiological PreservationCardiacCardiac MyocytesCell LineCell surfaceChronicClinicalCryopreservationDevicesDrug Delivery SystemsEncapsulatedEndothelial CellsEndotheliumEngineeringFutureGlareGraft RejectionHigh Pressure Liquid ChromatographyHourHumanImageImaging TechniquesImmune systemImmunofluorescence ImmunologicImmunosuppressionImmunosuppressive AgentsImmunotherapeutic agentIn VitroInbred BALB C MiceInflammationInflammatoryIntegrin alphaVbeta3LiteratureLongevityMainstreamingMeasuresMediationMediator of activation proteinMethodsMicellesModalityMusOrgan HarvestingsOrgan TransplantationOxidative StressPathologyPathway interactionsPerfusionPharmaceutical PreparationsPhenotypePhosphotransferasesPlayRGD (sequence)Research PersonnelResolutionResveratrolRoleSamplingSolidSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationStagingStaining methodStainsSurfaceSystemTherapeuticThrombosisTimeTissuesToxic effectTranslational ResearchTransplantationUmbilical veinUniversitiesWisconsinanalogcytokinedosageend-stage organ failurefluorophoreimprovedin vivonanoparticlenanotherapeuticnovelpolyphenolpreventpublic health relevancereceptor mediated endocytosistargeted deliverytherapeutic targettraffickinguptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Organ transplantation has become the modality for the treatment of end-stage organ failure. Chronic rejection remains a leading cause of graft loss in the long term. One of the primary reasons for this is that the adaptive immune system plays an integral role and is just emerging as a critical mediator in organ transplantation. Accumulating evidence indicates that the adaptive immune system is activated at the time of organ transplantation and remains in play longer than initially recognized by the release of inflammatory triggers, including oxidative stress. Various translational research efforts have identified pathways and potential therapeutics that may allay the effects of chronic rejection by conferring an enhanced inflammation resolution and a tolerogenic phenotype in allograft recipients. Polyphenols, such as resveratrol (RSV), reduce a range of pathologies associated with organ transplantation, including inflammation. The activities of these compounds are achieved via various mechanisms including their well-characterized antioxidant effects and immunosuppression effects. The clinical use of RSV is not; however, mainstream as issues regarding poor selectivity, dosage, toxicity and delivery methods are unresolved. Here, we propose a novel delivery method wherein an immunotherapeutic is encapsulated in a biologically inert nanoparticle and delivered in a targeted manner to an allograft in vivo. To this
end, we have generated RSV analogs to improve bioavailability and toxicity of RSV. The encapsulation of RSV analogs in micelle nanoparticles and its impact on harvested organs requires proof-of-concept studies. We will engineer a micelle nanoparticle which is conjugated to the amino acid sequence of Arg-Gly-Asp (cRGD), which serves as a targeting moiety directed towards the αvβ3 integrin on endothelial cells which optimizes cellular uptake. Near infrared fluorophores are also conjugated to the surface, allowing for analysis of micelle uptake and cellular localization within the endothelium of donor organ allografts. We hypothesize that targeted local delivery of packaged RSV via cold storage perfusion will increase concentrations of RSV intracellular and preserve aortic allograft cytoarchitecture.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Nanotherapeutic Delivery of Resveratrol Analogs as a Pre-Treatment of Allografts in Solid Organ Transplantation
-
批准号:9306943
-
项目类别:
-
资助金额:$7.48万
-
财政年份:2016
-
负责人:ANN-MARIE BROOME
-
依托单位:
Dual-Receptor Targeted Nanoparticles for Photodynamic Therapy of Brain Cancer
-
批准号:8542845
-
项目类别:
-
资助金额:$24.43万
-
财政年份:2010
-
负责人:ANN-MARIE BROOME
-
依托单位:
Dual-Receptor Targeted Nanoparticles for Photodynamic Therapy of Brain Cancer
-
批准号:8050347
-
项目类别:
-
资助金额:$34.34万
-
财政年份:2010
-
负责人:ANN-MARIE BROOME
-
依托单位:
Dual-Receptor Targeted Nanoparticles for Photodynamic Therapy of Brain Cancer
-
批准号:8665627
-
项目类别:
-
资助金额:$15.39万
-
财政年份:2010
-
负责人:ANN-MARIE BROOME
-
依托单位:
Imaging Complex Molecular Signatures in Cancer
-
批准号:8120244
-
项目类别:
-
资助金额:$11.2万
-
财政年份:2007
-
负责人:ANN-MARIE BROOME
-
依托单位:
Imaging Complex Molecular Signatures in Cancer
-
批准号:7917430
-
项目类别:
-
资助金额:$11.0万
-
财政年份:2007
-
负责人:ANN-MARIE BROOME
-
依托单位:
Imaging Complex Molecular Signatures in Cancer
-
批准号:7656635
-
项目类别:
-
资助金额:$9.8万
-
财政年份:2007
-
负责人:ANN-MARIE BROOME
-
依托单位:
Imaging Complex Molecular Signatures in Cancer
-
批准号:7318654
-
项目类别:
-
资助金额:$9.42万
-
财政年份:2007
-
负责人:ANN-MARIE BROOME
-
依托单位:
TNF-alpha Regulation of S100A9 in Human Keratinocytes
-
批准号:7502417
-
项目类别:
-
资助金额:$3.0万
-
财政年份:2007
-
负责人:ANN-MARIE BROOME
-
依托单位:
Imaging Complex Molecular Signatures in Cancer
-
批准号:7483008
-
项目类别:
-
资助金额:$9.61万
-
财政年份:2007
-
负责人:ANN-MARIE BROOME
-
依托单位:
海外基金